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C L I N I C A L R E S E A R C H A R T I C L E
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Epidemiology and Public Health, University College London, London WC1E 6BT, United Kingdom; 5First
Department of Medicine, Faculty of Medicine, Semmelweis University, 1083 Budapest, Hungary; 6National
Institute of Public Health, SouthernDenmark University, 1353Copenhagen, Denmark; 7Department of Sport
Medicine, Norwegian School of Sport Sciences, 0806 Oslo, Norway; and 8Norwegian Institute of Public
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Context: The effects of physical activity (PA) on improvement of glycemia may differ between
prediabetic individuals defined by oral glucose tolerance test vs glycated hemoglobin (HbA1c).
Objective:We studied the association between PA and improvement of glycemia in individuals with
prediabetes defined by glucose vs HbA1c criteria.
Design, Setting, and Participants: From the Whitehall II study, 957 participants with prediabetes
defined by isolated impaired fasting glucose (i-IFG), isolated impaired glucose tolerance (i-IGT), or
both and 457 with prediabetes defined by HbA1c were included.
Main Outcome Measures: The associations of PA with concomitant changes in glucose-related
outcomes during 5 years of follow-up were analyzed. A recursive partitioning analysis was
performed to study heterogeneity in the association between baseline PA and the probability
of reversion to normoglycemia.
Results: After 5 years of follow-up, 405 (42%) individuals with glucose-defined prediabetes reverted to
normal glucose tolerance (NGT). A 5-year increase in moderate-to-vigorous-intensity PA was associated
with improvements in insulin sensitivity and b-cell function, but PA was not generally associated with
reversion to NGT. Only among women $50 years with i-IFG or i-IGT, higher amounts of PA were
associatedwith higher probability of reversion toNGT. InHbA1c-definedprediabetes, only 20 individuals
(4.4%) reverted to normoglycemia, and PA was not associated with improvement in glycemic markers.
Conclusions: PAmay beparticularly important for reversion to normoglycemia amongolderwomen
with i-IFG or i-IGT. Individuals with prediabetes identified by HbA1c have a low probability of
reversion to normoglycemia, and their changes in glycemia are not related to PA. (J Clin Endocrinol
Metab 102: 3712–3721, 2017)
Intermediate hyperglycemia, also known as prediabetes,is associated with a high risk of developing type 2 di-
abetes and cardiovascular disease (1). Prediabetes can be
defined by measuring fasting plasma glucose (FPG) and/
or 2-hour plasma glucose (2hPG) concentration during
an oral glucose tolerance test (OGTT) (2, 3). More
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Abbreviations: 2hPG, 2-hour plasma glucose; ADA, American Diabetes Association; BMI,
body mass index; DPP, Diabetes Prevention Program; FPG, fasting plasma glucose; HbA1c,
glycated hemoglobin; HOMA, homeostatic model assessment; HOMA-IS, homeostatic
model assessment of insulin sensitivity; IFG, impaired fasting glucose; IGT, impaired
glucose tolerance; i-IFG, isolated impaired fasting glucose; i-IGT, isolated impaired glucose
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tolerance; OGTT, oral glucose tolerance test; PA, physical activity; TPA, total
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recently, also glycated hemoglobin (HbA1c) has been
adopted as a diagnostic tool to identify individuals with
prediabetes (2).
Strong evidence suggests that lifestyle modification,
including improvement in physical activity (PA), can
effectively lower diabetes and cardiovascular risk in in-
dividuals with impaired glucose tolerance (IGT) (4–7).
The evidence is less clear for individuals with isolated
impaired fasting glycemia (i-IFG) (8, 9) or people clas-
sified by the HbA1c criterion. Studies have also shown
that low levels of PA are predominantly associated with
metabolic defects related to IGT (systemic insulin resistance
and 2-hour hyperglycemia) as compared with i-IFG (de-
fective first-phase insulin secretion, decreased basal hepatic
glucose uptake, and fasting hyperglycemia) (9–12). Fur-
thermore, the Diabetes Prevention Program (DPP)
showed that lifestyle intervention was more effective
than metformin for 2hPG-defined diabetes, whereas
metformin and lifestyle intervention had a similar im-
pact on FPG concentrations (4, 13). Together these
findings suggest that individuals with i-IFG may not
have the same benefits on glucose regulation from in-
creasing PA as those with IGT (14). Studies examining
the effect of PA on markers of glucose regulation in
individuals with HbA1c-defined prediabetes are lacking.
The ultimate goal of diabetes prevention efforts is to
reduce the risk of future diabetes, cardiovascular disease,
and premature death. Results from the DPP showed that
prediabetic individuals who normalized their blood
glucose levels during the trial had significantly lower
diabetes and cardiovascular risk than those who main-
tained their prediabetes status during the study (15, 16).
Accordingly, the ability to restore normal glucose regu-
lation can be used as a marker of an individual’s future
risk. We hypothesized that the effects of PA on im-
provement of glycemia are different in prediabetic in-
dividuals defined by OGTT compared with HbA1c
criteria. We also hypothesized that within the group of
prediabetic individuals defined by the OGTT, those with
i-IFG have a smaller effect of daily PA on improvement of
glycemia than individuals with isolated impaired glucose
tolerance (i-IGT) or IFG+IGT. Thus, the overall objective
of this study was to examine heterogeneity in the asso-
ciation between PA and improvement in glycemia across
different diagnostic methods and within the OGTT
method. Specific aims were (1) to assess the strength of
the association of 5-year changes in PA with concomitant
changes in the levels of FPG, 2hPG, HbA1c, insulin
sensitivity, and b-cell function in prediabetes defined by
the glucose vs HbA1c criteria, and (2) to examine po-
tential heterogeneity in the association of baseline PA
with reversion to normoglycemia in prediabetic sub-
groups and across age, sex, and obesity degree.
Materials and Methods
Study participants
Participants are from theWhitehall II study, an occupational
cohort of 10,308 British civil servants (6896men, 3412women)
initially recruited in 1985. The study population consists of the
6479 people participating in at least two consecutive phases
(5-year observation windows) of the phases 5, 7, and/or 9 and
without known diabetes at their first measurement. These
phases are chosen because information on PA was not available
before phase 5.
For the analysis of prediabetes by the OGTT criteria, we
further excluded 6263 (34.0%) examinations for which the
participants had been fasting for fewer than 8 hours and 1415
(7.7%) examinations without both fasting and 2-hour glucose
measurements. Following this, 3348 participants remained with
valid 5-year follow-up data, of which 957 (28.6%) had pre-
diabetes at baseline according to the American Diabetes As-
sociation (ADA) glucose criteria (2) and were included in
this study.
AsHbA1c was notmeasured at phase 5, the study population
for analysis of prediabetes by the HbA1c criteria is based on the
5601 people participating at both phases 7 and 9 and without
known diabetes or HbA1c $6.5% at phase 7. We further ex-
cluded 698 participants (12.5%) without HbA1c measurement
at both baseline and follow-up, leaving 4903 participants free of
diabetes at baseline. Of these, 457 (9.3%) with prediabetes at
baseline according to the ADAHbA1c criteria (2) were included
in this study.
Measures of PA
A modified version of the previously validated Minnesota
Leisure-Time Physical Activity Questionnaire was used to de-
scribe typical weekly PA [metabolic equivalent (MET) hours per
week] (17). The questionnaire assessed both leisure-time and
job-related activities, but with more focus on leisure-time PA.
The questionnaire included 20 items on the amount of time
spent in the following activities: walking, sports, gardening,
housework, do-it-yourself activity, and other activities. For
each item, the participants were requested to provide the total
number of hours spent in that particular activity over the past
4 weeks. Subsequently, for each activity, a MET value was
assigned by using a compendium of activity energy costs (18).
One MET value reflects the metabolic cost during rest. The
intensity of PA was classified using multiples of 1MET; light-
intensity physical activity (LPA) was defined as activi-
ties .1.5 METs and ,3.0 METs (e.g., dishwashing), and
moderate-to-vigorous-intensity physical activity (MVPA) as
activities $3.0 METs (e.g., cycling or swimming). The total
number of MET-hours per week spent in LPA and MVPA
were calculated. Total physical activity (TPA) was defined as
the sum of LPA and MVPA.
Definition of prediabetes and measures of glycemia
At the clinical examinations at phases 5, 7, and 9, a standard
75-g OGTT was performed in the morning after $8 hours of
fasting or in the afternoon after no more than a light breakfast
eaten before 8:00 AM ($5 hours of fasting). Blood samples were
drawn before and 2 hours after the glucose ingestion. Pre-
diabetes was classified according to the ADA fasting and 2-hour
OGTT glucose criteria after $8 hours of fasting (2). I-IFG was
defined as FPG 5.6 to 6.9 mmol/L and 2hPG ,7.8 mmol/L,
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i-IGT as FPG ,5.6 and 2hPG 7.8 to 11.0 mmol/L, and com-
bined IFG+IGT as FPG $5.6 and 2hPG $7.8 mmol/L. At
phases 7 and 9, HbA1c was measured and prediabetes was
defined according to the ADA criterion as HbA1c 5.7% to 6.4%
(39 to 47mmol/mol).We further split the prediabetes group into
HbA1c 5.7% to 5.9% (39 to 41 mmol/mol) and HbA1c 6.0% to
6.4% (42 to 47 mmol/mol). We calculated two different indices
of insulin sensitivity, reflecting different aspects of insulin
sensitivity. The insulin sensitivity index (ISI0-120) was calculated
as a measure of whole-body insulin sensitivity using fasting and
2hPG and serum insulin concentrations (19). The homeostatic
model assessment (HOMA) was used to estimate insulin sen-
sitivity (1/HOMA-insulin resistance) in the fasting state (20),
mainly reflecting hepatic insulin sensitivity. HOMA-b was
calculated as a measure of b-cell function (20).
Assessment of clinical characteristics
At all clinical examinations, anthropometric measures
(weight, height, waist circumference) and blood pressure were
measured according to standard protocols (21). Information on
smoking status and occupation was gathered from question-
naire. During all phases, blood samples were handled according
to standardized procedures. Plasma glucose was measured by
the glucose oxidase method (22), serum insulin by in-house
radioimmunoassays (23), and cholesterol and triglyceride
concentrations by automated enzymatic colorimetric methods.
Low-density lipoprotein cholesterol was calculated with the
Friedewald formula.
Ethics
The UK National Health Service Health Research Authority
London–Harrow Ethics Committee reviewed and approved the
study. Written informed consent was obtained from each
participant at each examination phase. The study was con-
ducted according to the principles of the Helsinki Declaration.
Whitehall II data, protocols, and othermetadata are available to
bona fide researchers for research purposes. Please refer to the
Whitehall II data sharing policy at http://www.ucl.ac.uk/
whitehallII/data-sharing.
Statistical analysis
In linear regression models, we studied the association of
5-year changes in glycemic outcomes with concurrent 5-year
changes in LPA,MVPA, and TPA (MET-hours/week) adjusting
for age, sex, study phase, occupation, and baseline value of PA
and the outcome studied. LPA and MVPA were also adjusted
for TPA, so the interpretation of the results was that an increase
in LPAwas at the expense of a decrease inMVPA and vice versa
(i.e., isotemporal substitution). The following outcomes were
studied: FPG, 2hPG, HbA1c, HOMA-IS, HOMA-b, and ISI0-120.
Outcomes with a skewed distribution (HOMA-IS, HOMA-b,
and ISI0-120) were log-transformed prior to analysis. Except for
HbA1c, which was only measured at phases 7 and 9, the same
individual could contribute with up to three phases of exami-
nations, which gave rise to two 5-year periods of change in the
analysis of glucose-based prediabetes. To account for the likely
correlation of repeated measurements within the same partici-
pant, we usedmixed-effects models with a random intercept. In a
sensitivity analysis, we further assessed the mediating effect of
5-year change in body mass index (BMI) on the associations. In
the analysis of HbA1c defined prediabetes, we only had data for
phases 7 and 9, and therefore, a standard linear model was
used for all outcomes. In a sensitivity analysis, we limited the
analysis to phases 7 and 9 for the groupwith prediabetes by the
glucose criteria to explore the influence of phase 5 on the results
(n = 649).
The associations between baseline PA levels (LPA,MVPA,
and TPA) and reversion to normoglycemia after 5 years
were studied in age- and sex-adjusted Poisson regression
models with follow-up time as offset. LPA and MVPA were
additionally adjusted for TPA. We also tested for a modi-
fying effect of prediabetes subgroup on the association
between PA levels and the probability of reversion to
normoglycemia.
To further study potential heterogeneity in the effect of PAon
reversion to normoglycemia, we used recursive partitioning
modeling, including age, sex, BMI (normal weight, overweight,
obese), prediabetic subgroup, LPA, MVPA, and TPA as ex-
planatory variables. Recursive partitioning analysis is an ex-
ploratory method for identifying risk factors and interactions
among risk factors that may explain variation in a binary
outcome. At each node, the recursive partitioning algorithm
identifies the risk factor and split in this factor with the highest
discrimination power among all the factor-split combinations at
the node. For the development of the present model, the chosen
factor-split combination in each node was the one that gave the
maximal difference in the probability of reversion to normal
glucose tolerance (NGT) between the two resulting subgroups.
This procedure was applied recursively until the model was
grown to an optimal number of terminal nodes, meaning that
further splitting did not improve discrimination between par-
ticipants. Statistical analyses were performed in R version 3.2.3
and SAS version 9.4. A two-sided 5% level of significance
was used.
Results
Characteristics of the study population
Prediabetes by the glucose criteria
Characteristics of the study participants with pre-
diabetes by the glucose criteria at their first examination
are shown in Table 1. The proportion of men was higher
among individuals with i-IFG compared with individuals
with i-IGT or combined IFG+IGT. People with combined
IFG+IGT had in general a worse cardiometabolic risk
profile than those with the isolated forms of prediabetes.
Mean LPA, MVPA, or TPA levels did not differ between
the prediabetic groups at baseline (Table 1).
Prediabetes by the HbA1c criterion
Baseline characteristics of individuals with prediabetes
by the HbA1c criteria are shown in Table 1. Individuals
with higher HbA1c levels had higher mean 2hPG levels
and higher alcohol intake than individuals with lower
HbA1c levels. The levels of LPA, MVPA, and TPA and
most other parameters did not differ between people with
lower vs higher HbA1c levels, although there was a
tendency for a lower level of MVPA in those with the
highest HbA1c levels (Table 1).
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Relationship between 5-year changes in PA and
changes in markers of glycemia
Prediabetes by the glucose criteria
The associations of 5-year changes in PA with con-
comitant 5-year changes in glycemia are presented in
Table 2. Changes in LPA, MVPA, or TPA were not as-
sociated with changes in FPG, 2hPG, or HbA1c, but the
associations of higher levels of MVPA (at the expense of
lower levels of LPA) with reduction in 2hPG levels
approaching statistical significance (P = 0.060). Also, a
5-year increase of 10MET-h/wk inMVPA, at the expense
of a similar decrease in LPA, was associated with a 3% to
4% improvement in insulin sensitivity and reduction in
HOMA-b (Table 2). Further adjustment for 5-year
changes in BMI did not change the results (Supplemental
Table 1). Limiting the analysis to phases 7 and 9 only, the
CIs of the point estimates became slightly wider, but
the conclusions were similar (Supplemental Table 2).
Additionally, a 10 MET-h/wk increase in MVPA at the
expense of a decrease in LPA from phase 7 to 9 was
significantly associated with a 0.2 mmol/L reduction in
the 2hPG level in the sensitivity analysis (Supplemental
Table 1).
Prediabetes by the HbA1c criterion
Among individuals with prediabetes by HbA1c, 5-year
changes in LPA,MVPA, or TPAwere not associated with
reductions in HbA1c or with changes in any of the
glucose-related markers (Table 2). Adjustment for 5-year
changes in BMI did not change the results substantially.
However, an increase in PA was associated with 4 mmol/
L higher fasting plasma glucose concentration in the BMI-
adjusted analysis (Supplemental Table 1).
Relationship of baseline PA with 5-year reversion
to normoglycemia
Prediabetes by the glucose criteria
During the follow-up period, 405 (42%) individuals
reverted to NGT. Mean [95% confidence interval (CI)]
5-year reversion probabilities to NGT status were 31.9%
Table 1. Baseline Characteristics of the Study Population by Prediabetic Criteria
Prediabetes by Glucose Criteria Prediabetes by HbA1c Criterion





Participants 536 305 116 369 88
Men, % 86.6 (83.4 to 89.3) 75.1 (69.8 to 79.8)a 78.4 (69.9 to 85.5)a ,0.001 72.1 (67.2 to 76.6) 70.5 (59.8 to 79.7) 0.761
Age, y 57.2 (6.0) 59.7 (6.4)a 60.1 (6.5)a ,0.001 62.2 (6.1) 62.0 (5.7) 0.786
BMI, kg/m2 27.2 (3.8) 26.8 (4.2)a 28.2 (4.4)a 0.009 27.6 (4.2) 28.4 (4.8) 0.115
Waist circumference, cm 95.7 (10.6) 93.5 (11.8)a 97.3 (10.6)b 0.003 96.5 (11) 98.0 (11.3) 0.235
Total cholesterol,
mmol/L
5.9 (1.0) 5.9 (1.1) 5.9 (1.0) 0.978 5.8 (1.1) 5.7 (1.0) 0.156
Triglycerides, mmol/L 1.4 (0.9) 1.5 (0.8) 1.7 (1.0)a 0.004 1.6 (1.1) 1.6 (0.9) 0.626
Systolic BP, mm Hg 126.9 (15.7) 127.8 (17.1) 133.8 (15.8)a,b ,0.001 129.2 (15.8) 131.6 (19.8) 0.234
Diastolic BP, mm Hg 76.9 (9.8) 76.3 (10.9) 79.5 (10.1)a,b 0.017 75.5 (9.8) 75.6 (12.3) 0.954
Fasting plasma glucose,
mmol/L
5.9 (0.3) 5.1 (0.4)a 6.1 (0.3)a,b ,0.001 5.5 (0.6) 5.6 (0.6) 0.149
2hPG, mmol/L 5.8 (1.1) 8.7 (0.8)a 8.9 (0.9)a ,0.001 6.7 (1.7) 7.5 (1.8) 0.001
HbA1c, % 5.3 (0.3) 5.2 (0.4)
a 5.5 (0.4)a,b ,0.001 5.8 (0.1) 6.1 (0.1) ,0.001
HbA1c, mmol/mol 39.9 (4.0) 38.9 (4.3)
a 42.7 (4.9)a,b ,0.001 39.6 (0.9) 43.1 (1.2) ,0.001
Fasting serum insulin,
pmol/L
8.9 (8.5 to 9.3) 7.8 (7.3 to 8.4)a 10.6 (9.5 to 11.7)a,b ,0.001 8.6 (8.0 to 9.3) 9.7 (8.2 to 11.6) 0.171
2-h serum insulin,
pmol/L
34.0 (31.8 to 36.4) 73.7 (68.8 to 79.0)a 75.8 (67.9 to 84.5)a ,0.001 48.3 (43.1 to 54.1) 55.9 (44.2 to 70.6) 0.254
HOMA-IS 0.42 (0.41 to 0.45) 0.56 (0.52 to 0.6) 0.35 (0.32 to 0.39) ,0.001 0.48 (0.45 to 0.52) 0.39 (0.32 to 0.47) 0.013
HOMA-b 73.1 (69.7 to 76.7) 99.6 (93.0 to 106.7)a 82.3 (74.2 to 91.2)a,b ,0.001 87 (80.5 to 94.0) 94.4 (78.7 to 113.1) 0.369
ISI0-120 35.2 (34.2 to 36.3) 21.4 (20.9 to 21.9)
a 19.8 (19.0 to 20.7)a,b ,0.001 30.1 (28.6 to 31.7) 26.3 (23.5 to 29.5) 0.089
LPA, MET-h/wk 17.9 (17.0 to 18.9) 17.8 (16.5 to 19.3) 18.2 (15.9 to 20.9) 0.961 17.1 (15.7 to 18.6) 15.7 (13.7 to 18) 0.354
MVPA, MET-h/wk 13.8 (12.6 to 15.2) 13.8 (12.2 to 15.7) 14.8 (12.2 to 18.0) 0.818 12.3 (10.9 to 13.8) 9.6 (7.4 to 12.3) 0.064
TPA, MET-h/wk 34.4 (32.6 to 36.1) 33.4 (30.9 to 36.1) 33.1 (29.1 to 37.6) 0.759 31.1 (28.8 to 33.7) 28.1 (24.4 to 32.3) 0.257
Current smoker, % 8.6 (6.4 to 11.3) 6.6 (4.1 to 9.9) 12.1 (6.8 to 19.4) 0.194 9.8 (6.9 to 13.3) 9.1 (4.0 to 17.1) 0.848
Administrative
employment, %
40.7 (36.5 to 45.0) 33.4 (28.2 to 39) 37.1 (28.3 to 46.5) 0.112 30.9 (26.2 to 35.9) 27.3 (18.3 to 37.8) 0.503
Alcohol intake, units/wk 13.4 (12.3 to 14.5) 10.5 (9.3 to 11.8)a 11.0 (9.1 to 13.3) 0.002 8.0 (7.2 to 9.0) 10.9 (8.2 to 14.4) 0.030
Antihypertensive
treatment, %
17.0 (13.9 to 20.4) 23.9 (19.3 to 29.1)a 30.2 (22.0 to 39.4)a 0.002 28.7 (24.2 to 33.6) 44.3 (33.7 to 55.3) 0.006
Lipid-lowering
treatment, %
5.8 (4.0 to 8.1) 6.6 (4.1 to 9.9) 11.2 (6.1 to 18.4) 0.140 16.0 (12.4 to 20.1) 22.7 (14.5 to 32.9) 0.144
Abbreviation: BP, blood pressure.
Data are means (standard deviation), geometric means (95% CI), or proportions (95% CI). P is overall test of difference between groups.
aVersus i-IFG.
bVersus i-IGT.
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(95% CI, 28.8 to 35.3) in individuals with i-IFG, 31.0%
(95% CI, 26.7 to 35.7) in i-IGT and 18.5% (95% CI,
13.5 to 25.2) in combined IFG+IGT. We did not find a
modifying effect of prediabetic subgroup on the associ-
ation between PA and reversion to NGT (P $ 0.554).
Also, in the entire prediabetic population LPA,MVPA, or
TPA at baseline were not significantly associated with the
probability of reversion to NGT (P $ 0.085 for all).
Using recursive partitioning, we identified subgroups in
which TPA was associated with reversion to NGT (Fig. 1,
terminal nodes). The most significant predictor of re-
version to NGT was age, and the optimal split was at
50 years of age (Fig. 1, top). Among individuals below
50 years of age, sex was also associated with reversion to
NGT (P = 0.024). Here, the mean 5-year probability of
reversion to NGT was slightly lower among men (21.5%,
node 1) than among their female counterparts (26.9%,
node 2). For individuals aged 50 years or above, sex was
also significantly associated with reversion to NGT (P =
0.035). In addition, amongmen, prediabetic subgroupwas
associated with reversion to NGT (P = 0.031). Here men
with i-IFG had a higher 5-year probability of reversion to
NGT (33.3%, node 3) than those with i-IGT or combined
IFG+IGT (25.0%, node 4). Among older women, pre-
diabetic subgroup was also associated with reversion to
NGT with lower reversion probability in those with
IFG+IGT than the groupswith i-IFG or i-IGT (P = 0.021).
Additionally, among older women with i-IFG or i-IGT
the amount of TPAwas associated with the probability of
reversion to NGT (P = 0.032). The optimal split was at
56 MET-hours. Those with a weekly TPA level of #56
MET-hours had amean 5-year probability of reversion to
NGT of 34.3% (node 5). In contrast, 55.6% of those
with a weekly TPA level of .56 MET-hours reverted to
NGT (node 6). Among older women with IFG+IGT, the
5-year probability of reversion to NGT was only 16.0%
and this was not modified by baseline PA level (node 7).
By further studying the subgroups resulting from the
recursive partitioning analysis (nodes 1 to 7), we found
that the groups differed by other baseline characteristics
than those included in the model (Table 3). None of the
women $50 years with i-IFG or i-IGT who reported a
high amount of TPAwas a smoker or used lipid-lowering
treatment at baseline (node 6). Also, it was seen that older
women with IFG+IGT (node 7) had lower insulin sen-
sitivity at baseline compared with those with i-IFG or
i-IGT (node 6, P, 0.001). Among men$50 years, those
with i-IFG (node 3) had a higher level of ISI0-120 and
lower level of HOMA-b than those with i-IGT or
IFG+IGT (node 4, P , 0.001 for both).
Prediabetes by the HbA1c criterion
During 5 years of follow-up, only 20 (4.4%) individuals
withHbA1c-defined prediabetes reverted to normoglycemia
(HbA1c , 5.7%/39 mmol/mol). Five-year reversion prob-
abilities to normoglycemia were 4.7% (3.0 to 7.4) in in-
dividuals with HbA1c 5.7% to 5.9% (39 to 41 mmol/mol)
and 2.2% (0.6 to 8.6) in individuals with HbA1c 6.0% to
6.4% (42 to 47 mmol/mol). We did not find a modifying
effect of HbA1c subgroup on the association between
Table 2. Change inGlucose-RelatedOutcome (95%CI) by 10METHours perWeekHigher Level of LPA,MVPA,
or TPA During 5 Years of Follow-Up in Individuals With Prediabetes Diagnosed by the Glucose vs the
HbA1c Criteria
LPA MVPA TPA
Change P Change P Change P
Prediabetes by glucose criteria (n = 957)
Fasting plasma glucose, mmol/L 0.00 (–0.04 to 0.05) 0.829 0.00 (–0.05 to 0.04) 0.829 0.00 (–0.02 to 0.02) 0.678
2hPG, mmol/L 0.12 (–0.01 to 0.24) 0.060 20.12 (–0.24 to 0.01) 0.060 0.00 (–0.05 to 0.06) 0.876
HbA1c, % point 0.00 (–0.03 to 0.03) 0.956 0.00 (–0.03 to 0.03) 0.956 0.00 (–0.01 to 0.02) 0.618
HbA1c, mmol/mol 0.01 (–0.29 to 0.30) 0.956 20.01 (–0.3 to 0.29) 0.956 0.03 (–0.10 to 0.17) 0.618
HOMA-IS, % diff 23.9 (–6.5 to –1.3) 0.004 4.1 (1.3 to 7.0) 0.004 0.9 (–0.3 to 2.2) 0.154
HOMA-b, % diff 3.6 (1.1 to 6.2) 0.004 23.5 (–5.8 to –1.1) 0.004 20.9 (–2.0 to 0.2) 0.112
ISI0-120, % diff 23.2 (–5.1 to –1.3) 0.0010 3.3 (1.3 to 5.3) 0.001 0.3 (–0.6 to 1.2) 0.512
Prediabetes by HbA1c criterion (n = 457
a)
Fasting plasma glucose, mmol/L 20.01 (–0.09 to 0.07) 0.818 0.01 (–0.07 to 0.09) 0.818 0.03 (0.00 to 0.06) 0.078
2hPG, mmol/L 0.15 (–0.16 to 0.46) 0.341 20.15 (–0.46 to 0.16) 0.341 0.01 (–0.11 to 0.14) 0.835
HbA1c, % point 0.03 (–0.01 to 0.06) 0.150 20.03 (–0.06 to 0.01) 0.150 0.01 (–0.01 to 0.02) 0.500
HbA1c, mmol/mol 0.29 (–0.11 to 0.69) 0.150 20.29 (–0.69 to 0.11) 0.150 0.06 (–0.11 to 0.22) 0.500
HOMA-IS, % diff 21.3 (–7.7 to 5.4) 0.692 1.4 (–5.2 to 8.3) 0.692 20.2 (–2.8 to 2.5) 0.884
HOMA-b, % diff 20.9 (–6.7 to 5.1) 0.758 0.9 (–4.9 to 7.1) 0.758 21.9 (–4.2 to 0.4) 0.110
ISI0-120, % diff 21.0 (–5.9 to 4.2) 0.704 1.0 (–4.0 to 6.2) 0.704 0.6 (–1.5 to 2.6) 0.598
All analyses are adjusted for age, sex, study phase, occupation, and baseline value of PA and the outcome studied.MVPA and LPA are further adjusted for
TPA.
aExcept for HbA1c, only the subset fasting $8 hours at both baseline and follow-up were used in the analyses (n = 250).
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baseline PA and reversion to normoglycemia (P $ 0.107),
and neither PA, age, sex, BMI, nor the level of HbA1c was
associated with reversion to normoglycemia (P$ 0.255 for
all). Hence, a recursive partitioning model could not be
made for this group.
Discussion
It is well documented that lifestyle intervention including
high levels of PA can delay or even prevent the development
of type 2 diabetes in individuals with IGT (4–6), but the
evidence is less clear in individuals with prediabetes iden-
tified by FPG or HbA1c. We found that an increase in
MVPA over time at the expense of a decrease in LPA was
associatedwith subtle improvements in glycemicmarkers in
individuals with prediabetes defined by the glucose criteria.
PA was not a strong determinant for 5-year reversion to
normoglycemia in the entire prediabetic population, but
TPA was associated with 5-year reversion to NGT in
women with i-IFG or i-IGT aged 50 years or above.
Figure 1. Survival tree for reversion to NGT (prediabetes by glucose criteria). The black boxes 1 to 7 are the seven terminal nodes of the tree,
each with the number (n) of 5-year periods of change and their mean 5-year probability of reversion to NGT with 95% CI.
Table 3. Baseline Characteristics of the Study Population by Terminal Node of the Survival Tree
Node 1 Node 2 Node 3 Node 4 Node 5 Node 6 Node 7 P
Number of 5-y
periods of change
107 24 469 335 109 25 28
Men, % 100 0 100 100 0 0 0 ,0.001
Age, y 48.7 (1.4) 49.1 (1.5) 59.2 (5.2) 61.2 (5.8) 58.6 (4.7) 61.7 (6.0) 60.9 (6.3) ,0.001
BMI, kg/m2 27.6 (4.0) 29.3 (5.1) 27.1 (3.8) 27.2 (3.9) 27.3 (5.0) 26.5 (4.5) 29.1 (6.1) 0.042
HOMA-IS 0.40 (0.36 to 0.45) 0.41 (0.33 to 0.51) 0.43 (0.41 to 0.45) 0.47 (0.44 to 0.51) 0.51 (0.45 to 0.58) 0.55 (0.41 to 0.74) 0.34 (0.27 to 0.41) ,0.001
HOMA-b 87.8 (77.9 to 99.0) 85.4 (69.8 to 104.6) 71.5 (68.0 to 75.2) 90.6 (85.0 to 96.5) 91.4 (80.7 to 103.6) 83.0 (63.5 to 108.5) 87.1 (71.6 to 105.8) ,0.001
ISI0-120 30.9 (28.3 to 33.9) 27.1 (23.4 to 31.4) 35.0 (34.0 to 36.1) 20.9 (20.4 to 21.3) 26.8 (25.3 to 28.4) 25.7 (22.6 to 29.2) 19.2 (17.8 to 20.8) ,0.001
Current smoker, % 16.8 (10.3 to 25.3) 4.2 (0.1 to 21.1) 7.2 (5.1 to 10.0) 5.7 (3.4 to 8.7) 11.0 (5.8 to 18.4) 0 14.3 (4.0 to 32.7) 0.004
Administrative
employment, %
36.4 (27.4 to 46.3) 4.2 (0.1 to 21.1) 45.4 (40.8 to 50.0) 41.5 (36.2 to 47.0) 19.3 (12.3 to 27.9) 16.0 (4.5 to 36.1) 17.9 (6.1 to 36.9) ,0.001
LPA, MET-h/wk 15.6 (13.7 to 17.9) 19.1 (14.9 to 24.6) 17.8 (16.9 to 18.9) 17.3 (16.0 to 18.7) 19.4 (17.7 to 21.4) 39.1 (34.2 to 44.5) 19.9 (15.1 to 26.3) ,0.001
MVPA, MET-h/wk 9.3 (7.3 to 12.0) 11.2 (6.6 to 19.2) 15.1 (13.7 to 16.6) 16.3 (14.7 to 18.1) 6.2 (5.0 to 7.7) 29.0 (23.1 to 36.4) 11.8 (7.4 to 18.7) ,0.001
TPA, MET-h/wk 26.9 (23.4 to 30.9) 31.3 (24.2 to 40.4) 35.9 (34 to 37.9) 35.8 (33.4 to 38.3) 25.8 (23.3 to 28.6) 70.9 (64.7 to 77.6) 28.5 (20.9 to 38.9) ,0.001
Antihypertensive
treatment, %
6.5 (2.7 to 13.0) 16.7 (4.7 to 37.4) 19.2 (15.7 to 23.1) 30.1 (25.3 to 35.4) 18.3 (11.6 to 26.9) 20.0 (6.8 to 40.7) 25.0 (10.7 to 44.9) ,0.001
Lipid lowering
treatment, %
2.8 (0.6 to 8.0) 4.2 (0.1 to 21.1) 7.5 (5.3 to 10.2) 10.4 (7.4 to 14.2) 4.6 (1.5 to 10.4) 0 3.6 (0.1 to 18.3) 0.022
Data are means (standard deviation), geometric means (95% CI), or proportions (95% CI). P is overall test of difference between nodes.
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Reversion to normoglycemiawas rare among peoplewith
prediabetes based on theHbA1c criterion, and PAwas not
associated with improvements in glycemic markers in
this group.
We hypothesized that individuals with i-IFG would
have a smaller effect of PA levels on improvement of
glycemia than individuals with i-IGT or IFG+IGT, but
this could not be confirmed in the current study. Yet, the
fact that an increase in MVPA was associated with im-
provements in 2hPG and insulin sensitivity, but not with
reductions in FPG levels, support the notion that fasting
hyperglycemia is not modifiable by lifestyle factors to the
same extent as hyperglycemia after an OGTT (10, 24). A
previous longitudinal, observational, study found that
physical inactivity is not associated with progression to
type 2 diabetes in individuals with i-IFG (8). In support of
these findings, another study revealed that individualswith
i-IFG have the same levels of objectively measured daily
PA and cardiorespiratory fitness as individuals with
NGT (9). In the current study, the levels of self-reported
LPA, VPA, and TPA did not differ between the different
prediabetic groups. However, we found that individuals
with i-IFG—and, particularly, men $50 years—had
better whole-body insulin sensitivity (ISI0-120) at base-
line and a higher probability of reversion to NGT than
those with i-IGT or IFG+IGT. These findings could
suggest that differences in PA and other lifestyle-related
factors were present in the years before the baseline
examination.
Of the 457 individuals classified as having prediabetes
by the HbA1c criterion, only 20 reverted to normogly-
cemia during 5 years of follow-up, and we did not find
any determinants of reversion to normoglycemia in this
group. This finding underscores that individuals identi-
fied by HbA1c represent a different group than those
identified by the FPG or 2hPG criteria (25–27). A post
hoc analysis of the DPP supports this notion. It was found
that lifestyle intervention was not superior to metformin
on diabetes risk reduction when HbA1c was used as the
diagnostic tool instead of glucose (28). Our findings also
emphasize that HbA1c is a much more stable tool for
identifying prediabetes than fasting and 2-hour glucose,
which have high day-to-day variation (29) and thereby a
higher probability of misclassification and reversion to
NGT. Surrogate markers of insulin sensitivity and b-cell
function based on fasting and post-OGTT glucose and
insulin levels acutely respond to subtle changes in PA and
diet (30). In contrast, HbA1c reflects the average glycemic
level over the last 8 to 12 weeks and is thereby less re-
sponsive to daily behavioral changes (31). The mean
levels of FPG and 2hPG as well as insulin sensitivity and
beta cell function were in the normal range in participants
classified as having prediabetes by HbA1c. Hence, the
potential for improvement was also smaller in this group
than in those identified by the OGTT.
The general lack of association between PA and re-
duction in HbA1c is supported by previous research,
where no associations of PA energy expenditure or car-
diorespiratory fitness with HbA1c were found in a high-
risk population after adjustment for age, sex and obesity
degree (9). However, a small intervention study in 21
overweight and obese individuals with prediabetes
identified by HbA1c showed that 16 weeks of supervised
high-intensity interval or continuous moderate-intensity
training combined with resistance training resulted in a
mean reduction inHbA1c of 0.5% (;5mmol/mol) as well
as improvements in both insulin sensitivity and beta cell
function assessed by the HOMA model (32). Higher
obesity degree and higher baseline HbA1c levels of the
study population together with the long-term, supervised,
high-intensity intervention is likely to explain the bene-
ficial effects observed in this small study as compared
with our observational study.
An interesting finding from our study was that TPA
was particularly important for olderwomenwith i-IFG or
i-IGT in terms of normalizing their blood glucose levels. A
number of studies examining the effect of different life-
style interventions on diabetes prevention in individuals
with prediabetes have studied whether the effect of the
various interventions differ across sex and age in sub-
group analyses (33). Most intervention studies found no
sex differences in the effect of lifestyle interventions on
diabetes prevention or changes in glycemic parameters in
individuals with prediabetes (33, 34), potentially because
they were underpowered to look at those interactions or
because higher order interactions with other parameters
(e.g., age, obesity degree and prediabetic subgroup) were
not examined. However, in the DPP it was found that
among individuals with combined IFG+IGT men tended
to bemore likely than women to revert to NGT (16). Also
the DPP study found that men were more likely to revert
from combined IFG+IGT to i-IFG, whereas women were
more likely to revert from combined IFG+IGT to i-IGT
(16). This observation emphasizes differences in the sex
distribution across the prediabetic subgroups shown in
this study as well as in many other studies (35–38). Our
finding that age was an important determinant for re-
version to normoglycemia is also supported by results
from the DPP study showing that younger individuals
were more likely to revert from prediabetes to NGT than
older individuals (16). In terms of preventing diabetes
development (in contrast to reversion to NGT), the
Finnish Diabetes Prevention Study and the DPP found
that the effect of lifestyle intervention was greatest in
older age groups (4, 34), whichwas in alignment with our
finding where TPA was mainly predictive of reversion to
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NGT in women aged 50 years or above. A similar con-
clusion was made from a meta-analysis of twelve in-
tervention studies (39). The cut-point for TPA of 56
MET-h/wk was derived from the statistical model as
the optimal cut-point for discriminating between study
participants with different probabilities of reversion to
NGT. An amount of PA of 56MET-h/wk (;8MET-h/d)
can be achieved by, for example, 1 hour of brisk walking/
light bicycling and 30 minutes of running/jogging
each day.
Strengths of this study were the long follow-up time
and the detailed clinical data, includingOGTTs, collected
on a large number of individuals. Also, the availability of
concomitant measurements of glycemic markers and PA
facilitated modeling of temporal changes in PA patterns
and use of the isotemporal substitution model (40). This
model has become more common in recent years, and
has a clear advantage because of the easier interpretation
of substituting one type or intensity of PA with another.
Furthermore, the use of recursive partitioning as a sta-
tistical method enabled us to identify subgroups of pre-
diabetic individuals who may particularly benefit from
increasing their PA to normalize their blood glucose
levels. This finding would not have been revealed by
simple regression analysis, as we found no overall as-
sociation between PA and reversion to NGT in the entire
prediabetic population. A limitation of using recursive
partitioning is that some of the identified subgroups can
be relatively small. However, because this analysis was
not focused on developing a prediction model for re-
version to NGT but rather on a deeper understanding of
the associations between PA and improvement in gly-
cemia, we did not want to include a minimum group size
in the analysis. Another important issue to mention is the
number of tests performed in the analyses of associations
between changes in PA and glycemiamarkers.We did not
adjust for multiple testing in the results, because the
outcomes were predefined and highly correlated. How-
ever, even with adjustment for multiple testing (41), the
observed associations remained significant.
The Whitehall II study is an occupational cohort
consisting predominantly of white-collar workers, and
therefore, a certain degree of healthy worker effect may
be present in our study. Accordingly, our population may
be more homogeneous in terms of health status and PA
compared with the general population, which may limit
the possibility to detect meaningful associations. Detailed
information on habitual PA was assessed using a 20-item
questionnaire, allowing the quantification of a broad
range of activities, which were translated into intensities
using reference MET values (18). Although the ques-
tionnaire gives detailed information about PA behavior,
self-report measures of PA tend to overestimate PA levels
as compared with objectively measured PA (42). More
importantly, misreporting of PA seems to differ across
populations and subgroups of participants. A study
found that a 24-hour PA recall underestimatedMVPA for
younger normal weight individuals, but overestimated
MVPA for older, more obese individuals (43). This
suggests that the absolute levels of MVPA may be
overestimated in this rather homogeneous group of older
prediabetic individuals from the Whitehall II study, but
with no indication of differential misreporting across the
population. Accordingly, the reported associations are
likely unbiased from misreporting of PA.
In conclusion, among individuals with prediabetes
defined by the glucose criteria, substituting LPA with
MVPA was associated with improvements in 2hPG and
insulin sensitivity. We also showed that a high level of
TPA was particularly important for reversion to nor-
moglycemia among women aged$50 years with i-IFG or
i-IGT. Individuals identified as having prediabetes by
HbA1c had a low reversion rate to normoglycemia, and
their changes in glycemia were not associated with PA.
These findings highlight that heterogeneity in prediabetes
exists and that one-size-fits-all strategies for diabetes
prevention may not be feasible. Our results also question
whether results from large randomized diabetes pre-
vention trials in individuals with IGT (4–6) can be applied
to individuals identified with prediabetes by HbA1c. In-
deed, more evidence is needed regarding early prevention
of type 2 diabetes in individuals identified with pre-
diabetes by the HbA1c method (44).
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